Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 11, Issue 2, Pages e005968
Publisher
BMJ
Online
2023-02-23
DOI
10.1136/jitc-2022-005968
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies
- (2022) Gabriel Osborn et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Ovarian cancer‐specific dysregulated genes with prognostic significance: scRNA‐Seq with bulk RNA‐Seq data and experimental validation
- (2022) Chang Liu et al. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
- Clinical relevance of tumour-associated macrophages
- (2022) Mikael J. Pittet et al. Nature Reviews Clinical Oncology
- Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses
- (2022) Kunle Odunsi et al. Science Translational Medicine
- Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
- (2022) Junfen Xu et al. CLINICAL CANCER RESEARCH
- The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
- (2022) Yufei Xu et al. Frontiers in Immunology
- Metabolic Reprogramming in Tumor-Associated Macrophages in the Ovarian Tumor Microenvironment
- (2022) Sudhir Kumar et al. Cancers
- Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival
- (2022) Martijn Vlaming et al. Frontiers in Immunology
- CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
- (2021) Moran Yang et al. Journal for ImmunoTherapy of Cancer
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells
- (2021) Sijin Cheng et al. CELL
- CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy
- (2021) Alba Rodriguez-Garcia et al. Nature Communications
- A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors
- (2021) Gerald S. Falchook et al. INVESTIGATIONAL NEW DRUGS
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Andrés Poveda et al. LANCET ONCOLOGY
- Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy
- (2021) Tiziana Cotechini et al. Cells
- Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors’ Microenvironment
- (2021) Yanan Kang et al. BIOCONJUGATE CHEMISTRY
- GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
- (2021) Premal H. Thaker et al. CLINICAL CANCER RESEARCH
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
- (2021) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- A single-cell and spatially resolved atlas of human breast cancers
- (2021) Sunny Z. Wu et al. NATURE GENETICS
- Toll-Like Receptor-Based Strategies for Cancer Immunotherapy
- (2021) Saghar Pahlavanneshan et al. Journal of Immunology Research
- TPL Inhibits the Invasion and Migration of Drug-Resistant Ovarian Cancer by Targeting the PI3K/AKT/NF-κB-Signaling Pathway to Inhibit the Polarization of M2 TAMs
- (2021) Fuyin Le et al. Frontiers in Oncology
- Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer
- (2021) Qianxia Tan et al. Aging-US
- TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer
- (2021) Laura S.M. Lecker et al. CANCER RESEARCH
- Lymphocyte and macrophage infiltration in omental metastases indicates poor prognosis in advance stage epithelial ovarian cancer
- (2021) Tao Zhang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Targeting TREM2 on tumor-associated macrophages enhances immunotherapy
- (2021) Mikhail Binnewies et al. Cell Reports
- Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells
- (2021) Christina Pfirschke et al. Cancer Immunology Research
- Immunological configuration of ovarian carcinoma: features and impact on disease outcome
- (2021) Jitka Fucikova et al. Journal for ImmunoTherapy of Cancer
- Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment
- (2021) Racheal Louise Johnson et al. Cancers
- Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting
- (2021) Tetiana Hourani et al. Frontiers in Oncology
- High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition
- (2021) Ying Ni et al. npj Precision Oncology
- Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain
- (2020) Dayana Herrera-Rios et al. Frontiers in Immunology
- Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice
- (2020) Sharmilla Devi Jayasingam et al. Frontiers in Oncology
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma
- (2020) Amr Ahmed El-Arabey et al. CELLULAR SIGNALLING
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C
- (2020) Anna Mary Steitz et al. Cell Death & Disease
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients
- (2020) Antonio Macciò et al. Scientific Reports
- Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages
- (2020) Irina Larionova et al. Cancers
- The expanding landscape of inflammatory cells affecting cancer therapy
- (2020) Ralph Weissleder et al. Nature Biomedical Engineering
- TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy
- (2020) Martina Molgora et al. CELL
- Tumor associated macrophages in the molecular pathogenesis of ovarian cancer
- (2020) Yousef Yousefzadeh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance
- (2020) Leila Akkari et al. Science Translational Medicine
- Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis
- (2020) Houjun Xia et al. JCI Insight
- Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy
- (2020) Yanfei Yang et al. Frontiers in Cell and Developmental Biology
- Poly(ADP-ribose) polymerase inhibition: past, present and future
- (2020) Nicola J. Curtin et al. NATURE REVIEWS DRUG DISCOVERY
- 1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
- (2020) Huihan Ma et al. BMC Pharmacology & Toxicology
- M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
- (2020) Michal Hensler et al. Journal for ImmunoTherapy of Cancer
- Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
- (2020) Jean-Pascal Machiels et al. Journal for ImmunoTherapy of Cancer
- PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
- (2020) Maddison Rose et al. Frontiers in Cell and Developmental Biology
- Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1
- (2020) Venkatesh Krishnan et al. Communications Biology
- Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression
- (2019) Haimeng Yan et al. CANCER LETTERS
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
- (2019) Branimir I. Sikic et al. JOURNAL OF CLINICAL ONCOLOGY
- Macrophages in wound healing: activation and plasticity
- (2019) Sang Yong Kim et al. IMMUNOLOGY AND CELL BIOLOGY
- PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
- (2019) Patrick G. Pilié et al. CLINICAL CANCER RESEARCH
- Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression
- (2019) Pieter Goossens et al. Cell Metabolism
- CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
- (2019) Nicholas F. Kuhn et al. CANCER CELL
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages
- (2019) C A Gomez-Roca et al. ANNALS OF ONCOLOGY
- The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication
- (2019) Rosalba De Nola et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune checkpoint inhibitors: The linchpins of modern immunotherapy
- (2019) Breelyn A. Wilky IMMUNOLOGICAL REVIEWS
- Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
- (2019) Ignace Vergote et al. LANCET ONCOLOGY
- CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
- (2019) Amira A. Barkal et al. NATURE
- Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma
- (2019) Malgorzata Czystowska-Kuzmicz et al. Nature Communications
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- Diversity, Mechanisms, and Significance of Macrophage Plasticity
- (2019) Massimo Locati et al. Annual Review of Pathology-Mechanisms of Disease
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- (2019) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Prospects for combining immune checkpoint blockade with PARP inhibition
- (2019) Anping Li et al. Journal of Hematology & Oncology
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- A BISPECIFIC MOLECULE TARGETING CD40 AND TUMOR ANTIGEN MESOTHELIN ENHANCES TUMOR-SPECIFIC IMMUNITY
- (2019) Shiming Ye et al. Cancer Immunology Research
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
- (2019) Abhishek S. Kashyap et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment
- (2018) Meng Tang et al. CANCER SCIENCE
- Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
- (2018) David M. Hyman et al. CLINICAL CANCER RESEARCH
- Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
- (2018) Genevieve P Hartley et al. Cancer Immunology Research
- Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
- (2018) Flávia Castro et al. Frontiers in Immunology
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
- (2018) Asha Nayak-Kapoor et al. Journal for ImmunoTherapy of Cancer
- Abstract 3560: Targeting the MIF receptor CD74 in bladder cancer tumorigenesis
- (2018) Justin Penticuff et al. CANCER RESEARCH
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer
- (2018) Jieru Zhou et al. Cancer Immunology Research
- Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
- (2018) Takefumi Komiya et al. Frontiers in Oncology
- Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
- (2017) Xia Yuan et al. GYNECOLOGIC ONCOLOGY
- Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors
- (2017) Chelsea E. Gottlieb et al. GYNECOLOGIC ONCOLOGY
- A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
- (2017) Rebecca Kristeleit et al. GYNECOLOGIC ONCOLOGY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment
- (2017) Thomas Worzfeld et al. MOLECULAR & CELLULAR PROTEOMICS
- CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways
- (2017) Kiyoko Nakamura et al. ONCOLOGY REPORTS
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer
- (2017) Yusuke Kobayashi et al. Oncotarget
- Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy
- (2017) Yasmin A. Lyons et al. Oncotarget
- CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis
- (2017) Ran Liu et al. Oncotarget
- Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis
- (2017) Erika M. Palmieri et al. Cell Reports
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
- (2017) Thomas Worzfeld et al. Frontiers in Oncology
- The CD47 “don't eat me signal” is highly expressed in human ovarian cancer
- (2016) R.M. Brightwell et al. GYNECOLOGIC ONCOLOGY
- Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer
- (2016) Mingzhu Yin et al. JOURNAL OF CLINICAL INVESTIGATION
- Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
- (2016) Inga Bekes et al. Molecular Cancer
- CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
- (2016) Denis Lane et al. Molecular Cancer
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Differential distribution of tumor-associated macrophages and Treg/Th17 cells in the progression of malignant and benign epithelial ovarian tumors
- (2016) Qinyi Zhu et al. Oncology Letters
- The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization
- (2016) Florian Finkernagel et al. Oncotarget
- Targeting the CCL2-CCR2 signaling axis in cancer metastasis
- (2016) Su Yin Lim et al. Oncotarget
- Management of relapsed ovarian cancer: a review
- (2016) Gonzalo H. Giornelli SpringerPlus
- Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer
- (2015) D. L. Moughon et al. CANCER RESEARCH
- The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer
- (2015) Qiu-Xia Qu et al. TUMOR BIOLOGY
- Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment
- (2015) Tim Schumann et al. Oncotarget
- Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
- (2015) Lee B. Rivera et al. Cell Reports
- Overexpression of Semaphorin4D Indicates Poor Prognosis and Prompts Monocyte Differentiation toward M2 Macrophages in Epithelial Ovarian Cancer
- (2014) Ying Chen et al. Asian Pacific Journal of Cancer Prevention
- Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer
- (2014) Nicole M Reusser et al. CANCER BIOLOGY & THERAPY
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment
- (2014) Yuko Tanizaki et al. CANCER SCIENCE
- Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines
- (2014) Peter J. Murray et al. IMMUNITY
- Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers
- (2014) Francois Moisan et al. Molecular Oncology
- Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
- (2014) Oscar R. Colegio et al. NATURE
- Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration
- (2014) Z Wen et al. ONCOGENE
- Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
- (2014) Irene Brana et al. Targeted Oncology
- CSF-1 Receptor Signaling in Myeloid Cells
- (2014) E. R. Stanley et al. Cold Spring Harbor Perspectives in Biology
- A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients
- (2014) Meiying Zhang et al. Journal of Ovarian Research
- Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer
- (2014) Emily K. Colvin Frontiers in Oncology
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
- (2013) Shahneen K. Sandhu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population
- (2013) D. Laoui et al. CANCER RESEARCH
- Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer
- (2013) Khursheed Anwer et al. GYNECOLOGIC ONCOLOGY
- Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse
- (2013) Silke Reinartz et al. INTERNATIONAL JOURNAL OF CANCER
- High MUC2 Expression in Ovarian Cancer Is Inversely Associated with the M1/M2 Ratio of Tumor-Associated Macrophages and Patient Survival Time
- (2013) Yi-feng He et al. PLoS One
- Clearing the Dead: Apoptotic Cell Sensing, Recognition, Engulfment, and Digestion
- (2013) A. Hochreiter-Hufford et al. Cold Spring Harbor Perspectives in Biology
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- Cytokine gene expression signature in ovarian clear cell carcinoma
- (2012) NOZOMU YANAIHARA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN- and GM-CSF
- (2012) P. Spear et al. JOURNAL OF IMMUNOLOGY
- Therapeutic effect of recombinant plasmid-encoded human interleukin-12 in tumor-bearing mice
- (2012) YUNFANG SUN Molecular Medicine Reports
- BTN3A2 Expression in Epithelial Ovarian Cancer Is Associated with Higher Tumor Infiltrating T Cells and a Better Prognosis
- (2012) Cécile Le Page et al. PLoS One
- Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
- (2011) Denis Lane et al. BMC CANCER
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
- (2010) Melissa A. Geller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation
- (2010) Kiyomi Takaishi et al. CANCER SCIENCE
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer
- (2009) K Anwer et al. GENE THERAPY
- Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages
- (2009) Dorothée Duluc et al. INTERNATIONAL JOURNAL OF CANCER
- Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors
- (2009) Kyoko Kawamura et al. PATHOLOGY INTERNATIONAL
- Macrophage CD40 signaling: A pivotal regulator of disease protection and pathogenesis
- (2009) Jill Suttles et al. SEMINARS IN IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started